Medicine for treating fatty liver disease

• Main Authors: OHYABU NAOKI, YUKIOKA, HIDEO, SHIMAZAKI ATSUYUKI, HAMADA TADATERU
• Format: Patent
• Language: Chinese; English
• Published: 31.01.2023
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; STEROIDS

Provided is a pharmaceutical composition for the treatment and/or prevention of fatty liver diseases, particularly non-alcoholic fatty liver diseases, which has an excellent ACC2 selective inhibitory effect and does not accompany side effects such as an increase in plasma triglyceride or a decrease in platelet concentration. A pharmaceutical composition for treating and/or preventing fatty liver diseases, which contains a compound represented by formula (I) or a pharmaceutically acceptable salt thereof: (in the formula, R1 is a haloalkyl group or a non-aromatic carbocyclic group, R2 is a hydrogen atom or halogen, R3 is halogen, ring A is a group represented by formula:-L1-is-O-(CH2)-,-(CH2) 2-, etc. And R5 is an alkyl carbonyl group or a carbamoyl group. ). 本发明提供具有优良ACC2选择性抑制作用，不会伴随血浆甘油三酯上升或血小板浓度的降低等副作用，而用于脂肪性肝病，尤其非酒精性脂肪肝病的治疗和/或预防的药物组合物。一种用于治疗和/或预防脂肪性肝病的药物组合物，其含有式(I)所示的化合物或其药学上可接受的盐，该式(I)如下：(式中，R1为卤烷基或非芳香族碳环式基，R2为氢原子或卤素，R3为卤素，环A为式：所示的基，-L1-为-O-(CH2)-、-(CH2)2-等，R4为烷基或卤烷基，R5为烷基羰基或氨甲酰基。)。